MedCity News March 31, 2025
Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension faster and more robust.
The rise in direct-to-patient therapeutics access via online compounding pharmacies and other direct-to-patient sales models has increased the likelihood of patients utilizing medications alongside other therapeutics and with various complex co-morbidities.
With the growth of GLP-1 drugs and the associated direct-to-patient prescribing options, this category of drug is well-positioned to leverage real-world data to identify and demonstrate benefit for patients in other therapeutic areas – beyond current approvals in obesity and diabetes. While GLP-1 drugs are at the forefront of a renewed opportunity for real-world study and surveillance,...
Today's Sponsors
Today's Sponsor